Novartis Strikes Kymriah Outcome-Based Deal With German Insurers

Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.

GermanFlag — Novartis agrees a payment by outcomes deal in Germany For Kymriah

Novartis and GWQ, a group of German health insurers, are piloting an agreement that will see the Swiss pharma firm repay some of the cost of its CAR-T cell therapy Kymriah (tisagenlecleucel) if survival outcomes are not met. It is the first outcomes-based deal for an anticancer gene therapy and CAR-T therapy in Germany, say Novartis and GWQ.

With the aim of securing faster access for patients, the agreement will run until